BIVI News and Press, BioVie Inc. From 08/17/19

The August lull has set in and we're in the thick of it, with just two pricings this week and one postponement. The IPO pipeline is starting to fill up, with seven companies submitting initial filings led by The We Company (WE), a signal that the summer slowdown is coming to an end. Chinese ...

A Kansas bank and a Chinese fintech are scheduled for the week ahead, the last crop of offerings before the IPO market's annual August break. CrossFirst Bankshares (CFB) has about $4.6 billion in assets, with seven locations across KS, OK, TX, and MO. While its efficiency ratio and ROE are b...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

The summer IPO market is wrapping up. While we could see a few more launches, this week's five deals should be some of the last IPOs before the August break. A Chinese investment bank and an Israeli medical device maker are the two most notable IPOs. The other three include a micro-cap biote...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

Quick Take BioVie ( OTCQB:BIVI ) has filed to raise $15 million in a U.S. IPO, according to an amended registration statement . The company is developing a terlipressin-based therapy for the treatment of ascites. BIVI is a tiny biopharma with little in the way of resources and a long ro...

BioVie Inc. ( BIVI ) should not have an enterprise value of $31 million. At that mark, the company is a sell. Other peers exhibiting a more advanced pipeline have a valuation close to that of BioVie Inc. Besides, the number of operating risks is elevated. The most worrying is that a significan...

Quick Take BioVie ( OTCQB:BIVI ) has filed to raise gross proceeds of $23 million from a U.S. IPO, according to an S-1 registration statement . The firm is focused on the development of therapies for chronic liver diseases. BIVI hasn’t entered Phase 1 safety trials yet so is an u...

The IPO market is cooking. Six IPOs raised $1 billion this past week, with five notching double-digit gains. Beyond Meat (BYND) popped 163% in the biggest first-day pop since 2015. The vegan burger maker has had explosive growth (205% in the 1Q19), extremely rare for a food company, and like...

LOS ANGELES, April 30, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continu...